Tag: lead

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds Veritone, Inc. (“Veritone” or the “Company”) (NASDAQ:VERI) investors of the July 20, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Veritone securities between October 14, 2025 through April 14, 2026 (“the Class Period”).

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Company builds agentic AI operating systems that replace repetitive work and enable teams to scale faster with fewer resources

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).